

## ASX Announcement

### Race secures fifth US patent for Zantrene®

6 October 2021 – Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene® (bisantrene dihydrochloride).

This is Race’s fifth patent granted for Zantrene in the United States. *“This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene”,* said Race’s CEO & Managing Director, Phillip Lynch.

The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192) and in 2020 (US 10,548,876), further strengthening Race’s IP position for Zantrene.

The patent further expands Race’s IP portfolio in the therapeutic utility of Zantrene (and related chemical structures), in particular – for methods, formulations and compositions that improve the therapeutic efficacy of Zantrene and reduce side effects.

ENDS

#### About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene.

Learn more at [www.raceoncology.com](http://www.raceoncology.com).

#### Release authorised by:

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

#### Media contact:

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)